Publication: Multivalent ligand: Design principle for targeted therapeutic delivery approach
1
0
Issued Date
2012
Resource Type
File Type
application/pdf
ISSN
20415990
Other identifier(s)
2-s2.0-84867940749
Rights Holder(s)
มหาวิทยาลัยศรีนครินทรวิโรฒ
Bibliographic Citation
Therapeutic Delivery. Vol 3, No.10 (2012), p.1171-1187
Suggested Citation
Chittasupho C. Multivalent ligand: Design principle for targeted therapeutic delivery approach. Therapeutic Delivery. Vol 3, No.10 (2012), p.1171-1187. doi:10.4155/tde.12.99 Retrieved from: https://hdl.handle.net/20.500.14740/6965
Author(s)
Abstract
Multivalent interactions of biological molecules play an important role in many biochemical events. A multivalent ligand comprises of multiple copies of ligands conjugated to scaffolds, allowing the simultaneous binding of multivalent ligands to multiple binding sites or receptors. Many research groups have successfully designed and synthesized multivalent ligands to increase the binding affinity, avidity and specificity of the ligand to the receptor. A multimeric ligand is a promising option for the specific treatment of diseases. In this review, the factors affecting multivalent interactions, including the size and shape of the ligand, geometry and an arrangement of ligands on the scaffold, linker length, thermodynamic, and kinetics of the interactions are discussed. Examples of the multivalent ligand applications for therapeutic delivery are also summarized. © 2012 Future Science Ltd.
Subject(s)
Antibody
Antibody conjugate
Arginylglycylaspartic acid
Cancer vaccine
Carbohydrate
Cephalosporin
Cisplatin
Cytotoxic T lymphocyte antigen 4 antibody
Dendrimer
Doxorubicin
Ligand
Macrogol
Multivalent ligand
Nanoparticle
Peptide
Polyamidoamine
Polyglactin
Polymer
Single chain fragment variable antibody
Tumor antigen
Tumor vaccine
Unclassified drug
Very late activation antigen 4
Vitronectin receptor
Autoimmune disease
Binding affinity
Binding site
Breast cancer
Cancer immunotherapy
Concentration (parameters)
Conformational transition
Controlled drug release
Density
Drug delivery system
Drug half life
Encapsulation
Enthalpy
Entropy
Human
IC 50
Immunogenicity
Ligand binding
Molecular interaction
Molecularly targeted therapy
Nonhuman
Priority journal
Protein multimerization
Review
T lymphocyte activation
Thermodynamics
Animals
Binding Sites
Drug Delivery Systems
Drug Design
Humans
Ligands
Thermodynamics
Antibody conjugate
Arginylglycylaspartic acid
Cancer vaccine
Carbohydrate
Cephalosporin
Cisplatin
Cytotoxic T lymphocyte antigen 4 antibody
Dendrimer
Doxorubicin
Ligand
Macrogol
Multivalent ligand
Nanoparticle
Peptide
Polyamidoamine
Polyglactin
Polymer
Single chain fragment variable antibody
Tumor antigen
Tumor vaccine
Unclassified drug
Very late activation antigen 4
Vitronectin receptor
Autoimmune disease
Binding affinity
Binding site
Breast cancer
Cancer immunotherapy
Concentration (parameters)
Conformational transition
Controlled drug release
Density
Drug delivery system
Drug half life
Encapsulation
Enthalpy
Entropy
Human
IC 50
Immunogenicity
Ligand binding
Molecular interaction
Molecularly targeted therapy
Nonhuman
Priority journal
Protein multimerization
Review
T lymphocyte activation
Thermodynamics
Animals
Binding Sites
Drug Delivery Systems
Drug Design
Humans
Ligands
Thermodynamics